USA flag logo/image

An Official Website of the United States Government

Nanoparticles to Sequester and Facilitate In Vivo Excretion of Lipophilic…

Award Information

Agency:
Department of Defense
Branch:
Air Force
Award ID:
Program Year/Program:
2011 / STTR
Agency Tracking Number:
F10B-T24-0132
Solicitation Year:
2010
Solicitation Topic Code:
AF10-BT24
Solicitation Number:
2010.B
Small Business Information
ADA Technologies, Inc.
8100 Shaffer Parkway Suite #130 Littleton, CO 80127-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Nanoparticles to Sequester and Facilitate In Vivo Excretion of Lipophilic Molecules
Agency / Branch: DOD / USAF
Contract: FA9550-11-C-0083
Award Amount: $99,993.00
 

Abstract:

ABSTRACT: Mycotoxins are lipophilic agents derived from fungus that pose a significant public health problem around the world. The effects of mycotoxins include loss of human and animal life, increased healthcare and veterinary costs, reduced livestock production, and disposal of contaminated foods and feeds. Mycotoxins, such as aflatoxin and T-2 mycotoxins, have been reported to be weaponized as terrorism agents, suggesting the possibility of future deployment against military personnel is a real and present danger. Unfortunately, no effective treatment for mycotoxin exposure in either the acute or chronic setting currently exists. As a result, the United States Air Force has identified the need to fabricate a nanoparticle therapeutic that can sequester and then facilitate the excretion of mycotoxins. To address this need, ADA Technologies Inc. (ADA; Littleton, CO) and Professor Kenneth W. Hunter (University of Nevada at Reno) propose the development of nanoparticles with surface-bound biomolecules for the intravenous binding of lipophilic molecules, sequestration, and excretion from the human body BENEFIT: The proposed program will result in a nanoparticle therapeutic with the demonstrated ability of tightly binding and sequestering lipophilic molecules in solution. The result of the proposed program is anticipated to be the first commercial therapeutic for exposure to fungal toxins. Additional commercial applications may include diagnostics, sensors, and tools for the identification of various harmful molds.

Principal Investigator:

Steve Arzberger
Program Manager
(303) 792-5615
stevea@adatech.com

Business Contact:

Clifton H. Brown, Jr.
President&CEO
(303) 792-5615
cliffb@adatech.com
Small Business Information at Submission:

ADA Technologies, Inc.
8100 Shaffer Parkway Suite #130 Littleton, CO -

EIN/Tax ID: 840984053
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
University of Nevada
Microbiology&Immunology
199 / School of Medicine
Reno, NV 89557-0046
Contact: Kenneth H. Sc.D.
Contact Phone: (775) 327-5255